Molecular Diagnostics Market Hits US$ 39.5 Billion in 2022, Expected to Reach US$ 59.4 Billion by 2033 with a 4.2% CAGR, Persistence Market Research
16 janv. 2024 10h30 HE
|
Persistence Market Research
New York, Jan. 16, 2024 (GLOBE NEWSWIRE) -- The Molecular Diagnostics Market is experiencing robust growth due to technological advancements and increasing demand for personalized medicine. Key...
Genomic Cancer Testing is projected to Hit $45.92 Billion, Globally, by 2030 at 16.1% CAGR: Coherent Market Insights
07 nov. 2023 02h49 HE
|
CMI
Burlingame, Nov. 07, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, global genomic cancer testing market is estimated to be valued at US$ 16.15 billion in 2022 and is expected to...
Florida Cancer Specialists & Research Institute Celebrates Addition of Next-Generation Genomic Testing Capabilities to Advance Precision Oncology Approach to Patient Care
06 sept. 2022 12h26 HE
|
Florida Cancer Specialists & Research Institute
Fort Myers, Fla., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Florida Cancer Specialists & Research Institute, LLC (FCS) celebrated the addition of genomic testing capabilities at its Next Generation...
Genomic Data Analysis and Interpretation Market Size is projected to reach USD 2.15 Billion by 2030, growing at a CAGR of 10.25%: Straits Research
16 août 2022 12h10 HE
|
Straits Research
New York, United States, Aug. 16, 2022 (GLOBE NEWSWIRE) -- The term "NGS," for "high throughput sequencing," describes a wide range of cutting-edge sequencing methods. Researchers can study...
Heart Failure POC and LOC Devices Market to Hit $180.1 Million by 2028; Heart Failure POC & LOC Devices Industry CAGR of 16.5% between 2022-2028; Exclusive Insight Report [155 Pages] by Vantage Market Research
11 mars 2022 02h40 HE
|
Vantage Market Research
WASHINGTON, March 11, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research’s recent analysis of the Global Heart Failure POC & LOC Devices Market finds that factors such as, increasing geriatric...
ProPhase Labs Announces $6 Million Stock Repurchase Program
08 sept. 2021 08h30 HE
|
ProPhase Labs, Inc.
Garden City, NY, Sept. 08, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified biotech and genomics company, today announced that its Board of Directors has authorized the...
Genomic testing in the U.S. workplace
05 nov. 2020 10h00 HE
|
The Jackson Laboratory
Farmington, Conn., Nov. 05, 2020 (GLOBE NEWSWIRE) -- More than 157 million people in the U.S. receive their healthcare insurance through employer health plans. One potential means of enhancing...
Biotheranostics’ Breast Cancer Index IDEAL study expands clinical evidence for prediction of extended endocrine benefit to patients treated with aromatase inhibitors
29 oct. 2020 08h00 HE
|
Biotheranostics, Inc.
San Diego, CA, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Biotheranostics announces the publication of results from the IDEAL study in Clinical Cancer Research which reports novel findings of the Breast...
Biotheranostics’ Pivotal Clinical Study of the Breast Cancer Index® featured on the cover of the Annals of Oncology
24 févr. 2020 08h00 HE
|
Biotheranostics, Inc.
San Diego, CA, Feb. 24, 2020 (GLOBE NEWSWIRE) -- A pivotal clinical study validating Breast Cancer Index earns the distinction of being selected for the cover of the Annals of Oncology. The...
Breast Cancer Index® and new data on its power to predict extended endocrine therapy benefit presented at ASCO 2019
03 juin 2019 08h00 HE
|
Biotheranostics, Inc.
San Diego, CA, June 03, 2019 (GLOBE NEWSWIRE) -- Biotheranostics, Inc. announces new pivotal data on the Breast Cancer Index® (BCI) being presented at the ASCO conference June 3, 2019 that further...